Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

Clinical Trial Description

This dose escalation phase I study is to evaluate the safety and feasibility of iNO as adjunctive therapy in the treatment of AIS in adult patients with clinically significant strokes. iNO will act as a selective vasodilator to ischemic tissues in the brain, increasing perfusion to the area of the brain most at risk (penumbra) in AIS patients. This therapy will help to increase collateral circulation and perfusion to the penumbra, salvaging this tissue and limiting the volume of core infarct while mitigating reperfusion injury to the salvaged tissue. Protection of ischemic penumbra is paramount in IAMT stroke patients. IAMT to re-establish blood flow during AIS from a large vessel occlusion (LVO) reduces death and disability. Initially this intervention was recommended up until 6 hours after symptom onset, but more recently has proven safe and effective up to 16 and 24 hours after stroke onset in select patients. These studies have confirmed the long believed thought that supporting ischemic penumbra during AIS helps limit the size of the ultimate core infarct and therefore reduces disability and death from stroke. Treatment aimed at protecting ischemic penumbra is thus paramount to treatment and research endeavors in AIS patients. iNO protects ischemic penumbra. Nitric oxide is an endothelial-derived vasodilator and has been shown to mediate cytoprotection after ischemic reperfusion injury and appears to aid in ischemic preconditioning signaling pathways. iNO has been shown to cause selective dilation of arterioles in the ischemic penumbra of stroke and subarachnoid hemorrhage animal models, helping augment the cerebral microcirculation and improve penumbral blood flow. This has been shown to reduce ischemic brain damage, limit core infarct, and consistently improve neurological outcome in a middle cerebral artery AIS mouse model ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05871606
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact	Anna M Helms, RN
Phone	704-446-0473
Email	Anna.M.Helms@atriumhealth.org
Status	Not yet recruiting
Phase	Phase 1
Start date	June 2024
Completion date	July 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03239847` - Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring	N/A
Recruiting	`NCT03544801` - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting	`NCT06010823` - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants	N/A
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Recruiting	`NCT02472028` - Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals	Phase 4
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Active, not recruiting	`NCT01555411` - Akershus Cardiac Examination (ACE) 1950 Study
Completed	`NCT01304576` - Orientation Agnosia: Clinical and Anatomical Study	N/A
Completed	`NCT00049920` - The ARIC MRI Study	N/A
Completed	`NCT00049894` - Predictors of Recurrent Stroke in the PROGRESS Study	N/A
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed	`NCT00005562` - Coronary Artery Calcium, Exercise Tests, and CHD Outcome	N/A
Completed	`NCT00005395` - Honolulu Heart Program-Study of Stroke and Dementia	N/A
Completed	`NCT00000479` - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer	Phase 3
Completed	`NCT00005140` - Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago	N/A
Enrolling by invitation	`NCT00005485` - The Jackson Heart Study of Cardiovascular Disease Among African Americans
Recruiting	`NCT06275113` - BRING-UP Prevention
Completed	`NCT02702635` - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging	N/A
Recruiting	`NCT04336852` - Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function	N/A
Not yet recruiting	`NCT05892510` - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy — iNO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms